In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

At the moment, the recommended treatment for COPD in Europe is an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA), or LABA/LAMA dual ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...

Digital inhalers may help predict the occurrence of acute exacerbations of chronic obstructive pulmonary disease (COPD) for ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Between 14 days and 1 day out from an acute exacerbation of COPD, a digital inhaler measured significant drops in inhalation ...

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma ...